The Vanguard Study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection tests.
Katherine A Guthrie, Garnet L Anderson, Ari Bell-Brown...
https://pubmed.ncbi.nlm.nih.gov/42571808/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
24000
Participants Needed
45
Research Sites
21 weeks
Total Duration
Researchers are exploring how multi-cancer detection MCD tests might work as tools to screen for multiple cancers at once in adults aged 45 to 75 without cancer. The study aims to understand the performance of two different MCD tests compared to a control group and how patients and doctors handle both normal and abnormal test results. This feasibility study will inform future trials and help improve early cancer detection when treatment is most effective. Participants will be randomly assigned to one of three groups one group will undergo the Shield MCD test, another the Avantect MCD test, and the third will serve as a control group with blood collection only. Blood samples are collected at enrollment and again after one year. Participants at unblinded sites receive their test results, and those with abnormal findings follow up with their clinicians for further testing. After the active study period, participants are followed passively for up to 10 years. During the study, participants complete questionnaires and provide blood samples on schedule. Researchers collect medical record data and monitor participant adherence, diagnostic outcomes, anxiety related to testing, and the accuracy of the tests in predicting cancer origins. Primary outcomes include enrollment feasibility, questionnaire completion, blood sample provision, and follow-up retention. Secondary outcomes evaluate diagnostic resolution, complications, and psychological impact. This comprehensive approach helps assess the practical aspects of MCD testing and its potential role in cancer screening.
CONDITIONS
The Vanguard Study: Testing a New Way to Screen for Cancer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Shield MCD test | Avantect MCD test | Control: standard screening |
|---|---|---|---|
| What it is | A blood‑based multi‑cancer early detection test using the investigational Shield MCD assay | A blood‑based multi‑cancer early detection test using the investigational Avantect MCD assay | Standard cancer screening and diagnostic follow‑up practices used as the control pathway |
| Role in trial | Participants randomized to receive the Shield MCD test | Participants randomized to receive the Avantect MCD test | Participants randomized to the control arm following standard screening procedures |
| Primary use | Evaluate feasibility and performance of blood‑based MCD screening | Evaluate feasibility and performance of blood‑based MCD screening | Provide baseline standard‑of‑care screening outcomes for comparison |
| How it is given or performed | Blood sample collected and analyzed with the Shield assay at baseline and follow‑up | Blood sample collected and analyzed with the Avantect assay at baseline and follow‑up | Undergo routine screening and medical record review per standard practice |
| Evidence status | Under ongoing evaluation; performance metrics like sensitivity and specificity are being assessed | Under ongoing evaluation; performance metrics like sensitivity and specificity are being assessed | Established screening effectiveness per guideline‑recommended methods |
| Important risks | Risks uncertain and depend on follow‑up diagnostic procedures after abnormal results | Risks uncertain and depend on follow‑up diagnostic procedures after abnormal results | Safety profile based on standard diagnostic pathways; known risks from imaging and biopsy |
| Important limitations | Unknown real‑world sensitivity and specificity across cancer types; requires external validation | Unknown real‑world sensitivity and specificity across cancer types; requires external validation | Limited to cancers with established screening; many cancer types lack routine detection methods |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit at enrollment
Duration - 1 year
Participants undergo blood collection for multi-cancer detection testing at enrollment and again after one year. Those at unblinded sites receive test results; participants with abnormal results follow up with their clinician for further evaluation.
2 visits for blood collection
Duration - Up to 10 years
After testing, participants are followed passively for up to 10 years to observe long-term health outcomes and cancer diagnoses.
No required visits; health data collected from records
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Katherine A Guthrie, Garnet L Anderson, Ari Bell-Brown...
https://pubmed.ncbi.nlm.nih.gov/42571808/National Cancer Institute (NCI)
Lead Sponsor